Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study.

Autor: Sudaka A; Pathology unit, Centre Antoine Lacassagne, 33 Av de Valombrose, 06189 Nice cedex 2, France., Susini A, Lo Nigro C, Fischel JL, Toussan N, Formento P, Tonissi F, Lattanzio L, Russi E, Etienne-Grimaldi MC, Merlano M, Milano G
Jazyk: angličtina
Zdroj: Investigational new drugs [Invest New Drugs] 2013 Feb; Vol. 31 (1), pp. 59-65. Date of Electronic Publication: 2012 Jun 20.
DOI: 10.1007/s10637-012-9834-6
Abstrakt: Background: Radiotherapy (RT) is the standard treatment for uveal melanoma. However it can cause damage to the retina and optic nerve. This study examined the in vitro and in vivo effects of the anti-VEGF monoclonal antibody bevacizumab associated with radiotherapy (RT) on tumor growth and tumor proliferation and vasculature on OCM-1 human uveal melanoma cell line.
Methods: The anti-proliferative effects of bevacizumab, RT and their combination were tested both in vitro (OCM-1 cells co-cultured with HUVEC cells in Transwell plates) and in vivo (OCM-1 tumor xenografts in nude mice). In addition, treatment effects in vitro on VEGF secretion, as well as treatment effects in vivo on tumor proliferation (Ki67 labelling), tumor vasculature (VEGFR2 labelling) and VEGF tumoral concentration were analyzed.
Results: Bevacizumab given alone had a significant impact on tumor growth in vivo (and moderate effects in vitro). The bevacizumab-RT combination had additive effects in vitro (tumor cell proliferation) and in vivo (tumor growth), which translated into a significant decrease in Ki67 expression, VEGFR2 labelling and VEGF tumoral content.
Conclusions: The bevacizumab-RT combination could be a promising clinical option to explore for the management of human uveal melanoma, since it may allow RT dose reduction without loss of antitumor efficacy.
Databáze: MEDLINE
Externí odkaz: